Objective: To investigate the regulatory role of miR-17-5p in the osteogenic differentiation of suture mesenchymal stem cells (SuSCs) and further explore its potential mechanism. Methods: (1)SuSCs of the cranial suture in SD rats were extracted and cultured. After induction with osteogenic induction solution, the expression levels of osteogenic markers (ALP, OCN, Runx2, BMP2) were detected by alkaline phosphatase (ALP) staining, alizarin red staining and RT-qPCR, respectively. The osteogenic ability was identified, and the purity of the extracted SuSCs was identified by flow cytometry. (2)The overexpression and interference vectors of miR-17-5p were constructed and transfected into SuSCs cells. The expression levels of osteogenic markers (ALP, OCN, Runx2, BMP2) were detected by alkaline phosphatase (ALP) staining, alizarin red staining and RT-qPCR, respectively. The effects of overexpression or interference of miR-17-5p on osteogenic differentiation of SuSCs were detected. (3)After overexpressing or interfering with miR-17-5p and transfecting SuSCs cells, WB was used to detect the mechanism of its effect on TGF-β and Smad7. Results: SuSCs cells were successfully extracted. The results of ALP staining, alizarin red staining and RT-qPCR detection of osteogenesis-related markers (ALP, OCN, Runx2, BMP2) after overexpression of miR-17-5p in SuSCs showed a trend of promoting osteogenic differentiation. After SuSCs interfered with miR-17-5p, ALP staining, alizarin red staining and RT-qPCR detection of osteogenic markers (ALP, OCN, Runx2, BMP2) showed a trend of inhibiting osteogenic differentiation. WB results showed that compared with the blank control group, overexpression of miR-17-5p significantly increased the expression level of TGF-β protein and significantly decreased the expression level of Smad7 protein, while interfering with miR-17-5p showed the opposite results. Conclusion: miR-17-5p is involved in the osteogenic differentiation of SuSCs and exerts a critical regulatory role by modulating the TGF-β/Smad7 signaling pathway.
WANG Runze
,
HUO Yinping
,
CHEN Qi
,
SHAO Guo
,
ZHAO Zhijun
,
ZHANG Chunyang
,
FENG Shijun
. miR-17-5p regulates osteogenic differentiation through suture mesenchymal stem cells[J]. Journal of Baotou Medical College, 2025
, 41(9)
: 25
-32
.
DOI: 10.16833/j.cnki.jbmc.2025.09.005
[1] Li J, von Campe G, Pepe A, et al. Automatic skull defect restoration and cranial implant generation for cranioplasty[J]. Med Image Anal, 2021, 73: 102171.
[2] Xu S, Niu F, Chen Y, et al. Repairing Cranial Defect With Autogenous Mandibular Outer Plate[J]. J Craniofac Surg, 2020, 31(6): 1768-1772.
[3] McCarthy JG, Zide BM. The spectrum of calvarial bone grafting: introduction of the vascularized calvarial bone flap[J]. Plast Reconstr Surg, 1984, 74(1): 10-18.
[4] Teng SW, Lo YS, Liu WT, et al. A genome-wide comparison ofmesenchymal stem cells derived from human placenta and umbilical cord[J]. Taiwan J Obstet Gynecol, 2017, 56(5): 664-671.
[5] Park D, Spencer JA, Koh BI, et al. Endogenous bone marrow MSCs are dynamic, fate-restricted participants in bone maintenance and regeneration[J]. Cell Stem Cell, 2012, 10(3): 259-272.
[6] Weilner S, Grillari-Voglauer R, Redl H, et al. The role of microRNAs in cellular senescence and age-related conditions of cartilage and bone[J]. Acta Orthop, 2015, 86(1): 92-99.
[7] Weilner S, Schraml E, Wieser M, et al. Secreted microvesicular miR-31 inhibits osteogenic differentiation of mesenchymal stem cells[J]. Aging Cell, 2016, 15(4): 744-754.
[8] Mohan S, Wergedal JE, Das S, et al. Conditional disruption of miR17-92 cluster in collagen type I-producing osteoblasts results in reduced periosteal bone formation and bone anabolic response to exercise[J]. Physiol Genomics, 2015, 47(2): 33-43.
[9] Jia J, Feng X, Xu W, et al. MiR-17-5p modulates osteoblastic differentiation and cell proliferation by targeting SMAD7 in non-traumatic osteonecrosis[J]. Exp Mol Med, 2014, 46(7): e107.
[10] Liu W, Qi M, Konermann A, et al. The p53/miR-17/Smurf1 pathway mediates skeletal deformities in an age-related model via inhibiting the function of mesenchymal stem cells[J]. Aging (Albany NY), 2015, 7(3): 205-218.
[11] Zhu H, Kavsak P, Abdollah S, et al. A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation[J]. Nature, 1999, 400(6745): 687-693.
[12] Yu F, Guo Y, Chen B, et al. MicroRNA-17-5p activates hepatic stellate cells through targeting of Smad7[J]. Lab Invest, 2015, 95(7): 781-789.
[13] Zou ML, Chen ZH, Teng YY, et al. The Smad Dependent TGF-β and BMP Signaling Pathway in Bone Remodeling and Therapies[J]. Front Mol Biosci, 2021, 8: 593310.
[14] Otsuka M. Foreword. Bioceramic research on intelligent implants and drug delivery system[J]. Biol Pharm Bull, 2013, 36(11): 1653.
[15] 岳莹莹, 靳小雷. 颅缝间充质干细胞在颅缝早闭症中的研究进展[J]. 中华整形外科杂志, 2023, 39(9): 1028-1034
[16] Li W, Zhao J, Wang J, et al. ROCK-TAZ signaling axis regulates mechanical tension-induced osteogenic differentiation of rat cranial sagittal suture mesenchymal stem cells[J]. J Cell Physiol, 2020, 235(9): 5972-5984.
[17] Bai X, Hua S, Zhang J, et al. The MicroRNA Family Both in Normal Development and in Different Diseases: The miR-17-92 Cluster[J]. Biomed Res Int, 2019, 2019: 9450240.
[18] Zheng L, Tu Q, Meng S, et al. Runx2/DICER/miRNA Pathway in RegulatingOsteogenesis[J]. J Cell Physiol, 2017, 232(1): 182-191.
[19] Fang T, Wu Q, Zhou L, et al. miR-106b-5p and miR-17-5p suppress osteogenic differentiation by targeting Smad5 and inhibit bone formation[J]. Exp Cell Res, 2016, 347(1): 74-82.
[20] Li H, Li T, Wang S, et al. miR-17-5p and miR-106a areinvolved in the balance between osteogenic and adipogenic differentiation of adipose-derived mesenchymal stem cells[J]. Stem Cell Res, 2013, 10(3): 313-324.
[21] Wei B, Wei W, Zhao B, et al. Long non-coding RNA HOTAIR inhibits miR-17-5p to regulate osteogenic differentiation and proliferation in non-traumatic osteonecrosis of femoral head[J]. PLoS One, 2017, 12(2): e0169097.
[22] Humeres C, Shinde AV, Hanna A, et al. Smad7 effects on TGF-β and ErbB2 restrain myofibroblast activation and protect from postinfarction heart failure[J]. J Clin Invest, 2022, 132(3):e146926.
